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Progressive multiple sclerosis (MS) is a severely disabling neurological condition, and an effective
treatment is urgently needed. Recently, high-dose biotin has emerged as a promising therapy for affected
individuals. Initial clinical data have shown that daily doses of biotin of up to 300 mg can improve
objective measures of MS-related disability. In this article, we review the biology of biotin and explore
the properties of this ubiquitous coenzyme that may explain the encouraging responses seen in patients
with progressive MS. The gradual worsening of neurological disability in patients with progressive MS is
caused by progressive axonal loss or damage. The triggers for axonal loss in MS likely include both in-
ﬂammatory demyelination of the myelin sheath and primary neurodegeneration caused by a state of
virtual hypoxia within the neuron. Accordingly, targeting both these pathological processes could be
effective in the treatment of progressive MS. Biotin is an essential co-factor for ﬁve carboxylases involved
in fatty acid synthesis and energy production. We hypothesize that high-dose biotin is exerting a ther-
apeutic effect in patients with progressive MS through two different and complementary mechanisms:
by promoting axonal remyelination by enhancing myelin production and by reducing axonal hypoxia
through enhanced energy production.
This article is part of the Special Issue entitled ‘Oligodendrocytes in Health and Disease’.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Multiple sclerosis (MS) affects an estimated 2.3 million people
worldwide (Browne et al., 2014). MS is the most common disabling
neurological disease of young adults, with ﬁrst symptoms typically
manifesting between 20 and 40 years of age (Browne et al., 2014).
The condition is more common in women than men, and preva-
lence generally increases with latitude (Simpson et al., 2011). In
Europe, the highest prevalence of MS is seen in Nordic countries
and the British Isles (Kingwell et al., 2013). A diagnosis of MS places
a high burden on the affected individual, both economically and
with respect to MS-associated disability (Pike et al., 2012).
In the majority (85%) of cases, patients experience an initial
phase of relapsing-remitting neurological dysfunction (RRMS),
which typically evolves into a secondary progressive disease at a
later point in the clinical course (SPMS) (Confavreux et al., 2000).
Once MS is in the progressive phase, individuals experience a
gradual worsening of neurological disability leading to problems
with vision, walking, balance, incontinence, cognitive changes, fa-
tigue, and pain (Gibson and Frank, 2002). Primary progressive MS
(PPMS), characterized by disease progression from onset, is less
common, affecting 10e15% of patients (Confavreux et al., 2000;
Koch et al., 2009). Despite these different initial clinical pheno-
types, the time to reach certain disability milestones and the ages at
which the milestones are reached are similar for all patients with
progressive MS (Confavreux and Vukusic, 2006).
Treatment options for MS remain inadequate. Most currently
approved therapies for MS target inﬂammatory processes and aim
to reduce the frequency of exacerbations in patients with RRMS.
These include b-interferons, dimethyl fumarate, glatiramer acetate,
ﬁngolimod, teriﬂunomide, and natalizumab (Wingerchuk and
Carter, 2014). b-interferon (Trojano et al., 2007), teriﬂunomide
(Confavreux et al., 2014), ﬁngolimod (Kappos et al., 2010), alem-
tuzumab (Coles et al., 2012), natalizumab (Polman et al., 2006), and
mitoxantrone (Martinelli et al., 2013) may also delay or reduce the
risk of disability progression. However, currently available treat-
ments have little to no efﬁcacy in patients with progressive MS,
particularly if superimposed relapses are absent, and there is no
pharmacological therapy capable of arresting or reversing MS-
related disability (Comi, 2013). Encouraging results have recently
been reported with the use of nonmyeloablative hematopoietic
stem cell transplantation in patients with RRMS (Burt et al., 2015).
This technique achieved a striking improvement in disability (as
measured by the Expanded Disability Status Scale; EDSS) in
approximately half of the patients at 2-year follow-up; moreover,
80% of patients remained relapse free at 4-year follow-up. However,
no beneﬁt was seen in patients who had progressive MS at the time
of transplant. For these individuals, an effective treatment remains
a signiﬁcant unmet medical need.
Two promyelinogenic agents are currently in development
as treatment for MS. LINGO-1 (leucine-rich repeat and
immunoglobulin-like domain-containing nogo receptor-interacting
protein 1) inhibits the differentiation of oligodendrocyte precursor
cells (OPCs) and consequently inhibits myelination (Jepson et al.,
2012). Upregulation of this receptor is seen in many neurological
disorders, including in OPCs found within areas of demyelination
from patients with MS (Mi et al., 2013). Inhibition of LINGO-1 inanimal models of autoimmune encephalomyelitis results in the
formation of newmyelin sheaths (Mi et al., 2007). Phase I data from
healthy volunteers and patients with MS indicate that inhibition of
LINGO-1 with the monoclonal antibody BIIB033 (Biogen Idec) ap-
pears to be well tolerated and a phase II trial in patients with RRMS
is ongoing (EUDRACT #: 2011-006262-40). First results have been
presented at the American Academy of Neurology. In the per-
protocol population, the anti-LINGO-1 group showed signiﬁcantly
improved optic nerve conduction latency vs placebo atWeek 32. No
statistical difference was observed in the ITT population or for the
secondary endpoints including visual acuity at low contrast
(Cadavid et al., 2015). In addition, a recombinant form of a human
IgM (rHIgM22; Acorda Therapeutics) that binds to myelin and the
surface of oligodendrocytes has been shown to promote remyeli-
nation in murine models of MS and other demyelinating diseases
(Mitsunaga et al., 2002; Warrington et al., 2007). The safety and
preliminary efﬁcacy of rHIgM22 are currently being investigated in
patients with all forms of MS in a phase I trial (NCT01803867).
In this paper, we review recently published data that suggest
that high-dose biotin is an effective treatment for patients with
progressive MS and propose two distinct (and complementary)
mechanisms of action to explain this efﬁcacy.2. Etiology and pathogenesis of MS
Despite decades of research into the biology of MS, the etiology
of this progressive neurological disease remains incompletely un-
derstood. Multiple sclerosis is classically considered to be an
autoimmune demyelination disorder in which activated T-cells
migrate across the blood brain barrier and attack the insulating
myelin sheath that surrounds the axons (Compston and Coles,
2008). This leads to a progressive demyelination of the axons that
ultimately culminates in degeneration of the denuded neurons.
Indeed, there is abundant evidence supporting the inﬂammatory
component of MS. Acute inﬂammatory lesions are characterized by
the presence of inﬁltrating activated T-cells (both CD4þ and CD8þ)
(Denic et al., 2013; Traugott et al., 1983), and the frequency of
axonal damage is related to the degree of inﬂammation within le-
sions (Trapp et al., 1998). Inﬂammation is initially transient and
remyelination of axons occurs (Olsen and Akirav, 2015), which may
explain the relapsing-remitting nature of the signs and symptoms
of RRMS. If demyelination persists, denuded axons are vulnerable to
damage and these immune-mediated attacks lead to axonal injury
and neuronal death (Brugarolas and Popko, 2014; Podbielska et al.,
2013).
However, autoimmunity alone fails to fully explain the patho-
physiology of MS. In particular, axonal degradation can occur in
normal-appearing white matter that has no evidence of myelin loss
(Bjartmar et al., 2001; Lovas et al., 2000) or inﬂammation (Bitsch
et al., 2000; Dutta and Trapp, 2011), and axonal degradation can
occur at all stages of MS disease progression (De Stefano et al.,
2001; Levin et al., 2014; Trapp et al., 1998). An alternative theory
proposes that MS is primarily a neurodegenerative disorder in
which the inﬂammatory responses observed in patients with MS
arise in response to highly antigenic components that are released
during degradation of the neurons (Bruck, 2005; Stys et al., 2012;
Trapp and Nave, 2008). Regardless of whether neurodegeneration
F. Sedel et al. / Neuropharmacology 110 (2016) 644e653646occurs secondary to demyelination or whether primary neuro-
degeneration is the trigger for inﬂammatory demyelination, axonal
loss or damage is undeniably the cause for the progressive neuro-
logical disability seen inMS (Bjartmar et al., 2000, 2003; De Stefano
et al., 1998; Dutta and Trapp, 2007). The exact mechanisms un-
derlying neurodegeneration remain poorly understood but are
believed to include a combination of energy imbalance, CD8þ cells,
glutamate, nitric oxide, and loss of trophic interaction with oligo-
dendrocytes (Bitsch et al., 2000; Bjartmar et al., 2003; Bruck, 2005).
3. High-dose biotin as a treatment for MS
MD1003 (MedDay Pharmaceuticals, Paris, France) is an oral
formulation of high-dose pharmaceutical-grade biotin currently in
clinical development as a treatment for progressive MS and adre-
nomyeloneuropathy (AMN). The daily dose of MD1003 currently
being investigated in phase III trials (300 mg biotin) is 10,000-fold
higher than the Adequate Intake (AI)e the daily dietary intake level
of biotin that is considered sufﬁcient for the maintenance of health
by the Food and Nutrition Board of the Institute of Medicine is
30 mg/day for adults (IOM Standing Committee on the Scientiﬁc
Evaluation of Dietary Reference Intervals, 1998). At 300 mg per
day, biotin is considered by regulators to be an active pharmaceu-
tical agent. Therefore, the efﬁcacy and safety of high-dose biotin as
a therapeutic option in MS require careful investigation prior to
being made available for clinical use.
Clinical data from the ﬁrst patients treated with MD1003 have
recently been published (Sedel et al., 2015). This open-label pilot
trial investigated daily administration of high-dose biotin
(100e300 mg/day) in 23 patients with primary or secondary pro-
gressive MS who received MD1003 for a mean duration of 9.2
months (range 2e36 months). Over 90% of the patients (21/23)
exhibited some degree of qualitative or quantitative clinical
improvement following MD1003 therapy including reduced MS-
related disability. A beneﬁcial effect was seen in all forms of pro-
gressive MS. Improvements in walking distance, EDSS values, and
time to walk 25 feet (TW25) were observed in patients with
prominent spinal cord involvement, and improvements in visual
acuity and the progressive reappearance of visual evoked potentials
with normal latencies were recorded in patients with visual
impairment related to optic nerve injury (Sedel et al., 2015). The
promising efﬁcacy observed in this pilot study suggests that high-
dose biotin is effective in both reversing disease progression and
reducing chronic disability. The study has important methodolog-
ical limitations including the small number of patients, the small
number of centers, the lack of a placebo or control group, the
heterogeneity of patients enrolled, the heterogeneity of evaluation
criteria, and the fact that treating and assessing physicians were the
same. Results of a double-blind, placebo-controlled, multisite study
were presented in April at the American Academy of Neurology
(Tourbah et al., 2015a). 154 patients were randomized, (103
received 300 mg of biotin per day and 51 received a placebo). Pa-
tients had secondary or primary progressive MS with EDSS be-
tween 4.5 and 7 and evidence of EDSS progression within the past
two years. Treatment durationwas 48weeks. The primary endpoint
was the proportion of patients who improved at month 9 and
conﬁrmed at month 12, deﬁned as decreased EDSS (by at least 1
point for EDSS 5.5 and 0.5 point for EDSS 6) or improved TW25
of at least 20%. A signiﬁcant proportion of biotin-treated patients
achieved the primary endpoint versus none of 51 placebo-treated
patients (p ¼ 0.0051). The primary endpoint was conﬁrmed by a
signiﬁcant decrease in the mean change in EDSS and the Clinical
Global Impression Scale assessed by the investigator and subject in
the biotin group (Tourbah et al., 2015b). We are hopeful that these
results ultimately represent a major breakthrough in the treatmentof MS because no therapeutic options have yet been validated to
treat the progressive (primary or secondary) forms of the disease
and its sequelae-related symptoms. In each patient treated with
MD1003, there was a delay between the onset of treatment and the
onset of objective clinical improvement; delays ranged from 2 to 8
months. This tantalizing observation suggests that MD1003 is
triggering some form of slowly progressive repair and furthermore
may act as a disease-modifying therapy in patients with progres-
sive disease. Both the compassionate use open-label study and the
placebo-controlled trial after 12 months' follow-up are however of
insufﬁcient duration to answer this question. Data from the 12-
month extension phase of this trial (during which all participants
receive high-dose biotin) are expected in January 2016 and will be
important in assessing the impact of the drug on long-term
disability progression.
4. The role of biotin in brain chemistry
Biotin (vitamin H) is a ubiquitous B-complex vitamin that acts as
an essential coenzyme for ﬁve essential carboxylases: pyruvate
carboxylase (PC) 3-methylcrotonyl-CoA carboxylase (MCC),
propionyl-CoA carboxylase (PCC), and the two isoforms of acetyl-
CoA carboxylase (ACC1 and ACC2) (Tong, 2013; Zempleni et al.,
2009). Biotin is covalently bound to speciﬁc lysine residues on
apocarboxylases; the biotinylation reaction is catalyzed by hol-
ocarboxylase synthetase (HLCS), an ATP-dependent enzyme enco-
ded by the HLCS gene (Chapman-Smith and Cronan, 1999). Once
bound, biotin acts as a transporter of an activated carboxyl moiety
in a variety of carboxylation reactions involved in energy meta-
bolism, fatty acid synthesis, and amino acid catabolism (Tong,
2013). The central role of biotin in intermediary metabolism is
likely responsible for the observation that biotin is required by all
tissues of the body; however, biotin appears to play a particularly
important role in brain chemistry. In contrast to liver, kidney, and
brain, biotin is present in relatively small amounts in many tissues
(a fact on which many (strept-)avidin-biotin histochemical tech-
niques rely); however, studies in the rat have demonstrated that
signiﬁcant levels of covalently bound biotin are found in the brain,
particularly in the cerebellar motor system and the brainstem
auditory system (McKay et al., 2004). Biotin is actively transported
across the human bloodebrain barrier (BBB) predominantly via the
Naþ-dependent multivitamin transporter (SLC5A6/SMVT; Uchida
et al. (2015)). This transporter has an estimated half-saturation
concentration (Km) of roughly 100 mM in rats (Spector and Mock,
1987), 35 mM in mice (Park and Sinko, 2005) and 20 mM in rab-
bits (Spector and Mock, 1988a). By extrapolation of data obtained
with smaller doses (Mock and Mock, 1997; Zempleni et al., 2001),
assuming dose proportionality, high doses of biotin in the 300 mg/
day range would result in plasma concentrations of biotin of about
5 mM, which theoretically would not be saturating the biotin
transporter (Spector and Johanson, 2007). Consistent with these
data, biotin concentration was shown to increase from about 0.1 to
6 nmol/g of brain tissue in juvenile rats given increasing oral doses
of biotin corresponding to about 0.3 mge3 mg/kg body weight in
humans, the highest dose being closest to the human therapeutic
dose given in progressive MS (Sawamura et al., 2007). Biotin con-
centration also increased in other tissues evaluated, namely skel-
etal muscle, heart, kidney, lung, spleen and testis. Within animal
brain, limited data indicate that biotin is localized to the oligo-
dendrocytes (LeVine and Macklin, 1988; Wang and Pevsner, 1999)
and in some neurons (McKay et al., 2004). Interestingly, levels of
covalently bound biotin and the expression of HCLS, biotin-
dependent carboxylases, and genes involved in biotin transport
and biotin recycling are maintained in the brain during periods of
biotin deﬁciency at the expense of other tissues such as liver
Fig. 1. Biotin activates myelin formation in oligodendrocytes through its role as a
cofactor for ACC. ACC is the rate limiting and committing step for the synthesis of
malonyl-CoA, the building block for fatty acids synthesis. ACC activity is detected at a
high level in oligodendrocytes in the brain. It is hypothesized that high doses of biotin
may result in increased fatty acid synthesis required for myelin repair.
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Melendez et al., 2001; Sander et al., 1982).
Further evidence for the vital role of biotin in neuron function
comes from the observation that neurological dysfunction is
prominent in patients with biotin deﬁciency and inborn errors of
biotinmetabolism (Wolf, 2011;Wolf and Feldman,1982). Biotin has
a vital role in the treatment of the orphan neurological disease
biotin-thiamine responsive basal ganglia disease (BTBGD). This
autosomal recessive disorder is caused by inherited mutations in
the gene encoding a transmembrane thiamine transporter that was
originally termed solute carrier family 19 member 3 [SLC19A3] but
now more commonly known as thiamine transporter 2 (THTR2)
(Said et al., 2004; Zeng et al., 2005). The symptoms of BTBGD are
severe and are characterized by recurrent subacute onset of en-
cephalopathy that manifest as confusion, seizures, dysarthria,
ataxia, dystonia, supranuclear facial palsy and even coma (Ozand
et al., 1998; Tabarki et al., 2013). Despite the fact that THTR2 is
not a biotin transporter in studies in hepatic, intestinal, or neuronal
cell lines (Subramanian et al., 2006), the condition is effectively and
rapidly treated with high-dose biotin (5e10 mg/kg/day) (Bindu
et al., 2009; Ozand et al., 1998).
5. Hypothesized modes of action of high-dose biotin in the
treatment of progressive MS
We hypothesize that high-dose biotin exerts its therapeutic ef-
fect in progressive MS through two primary mechanisms: 1) pro-
motion of remyelination through enhanced myelin formation in
oligodendrocytes, and 2) enhancement of brain energy production,
thereby protecting demyelinated axons from degradation.
5.1. High-dose biotin as a promoter of myelination through
enhanced myelin formation in oligodendrocytes
Through its role as an essential cofactor for ACC1 and ACC2,
high-dose biotin may be promoting remyelination by increasing
the availability of the fundamental building blocks required for
myelin membrane synthesis. ACC1 and ACC2 are encoded by two
distinct genes (ACACA and ACACB) and have distinct subcellular
locations and distinct metabolic roles. ACC1 catalyzes the rate
limiting, committed step in fatty acid biosynthesis: the cytosolic
synthesis of malonyl-CoA from acetyl-CoA (Fig. 1) (Foster, 2012;
Tong, 2013). A role for ACC in promoting myelination is supported
by several observations. Within the CNS, ACC appears to be pri-
marily expressed in oligodendrocytes, the cells specialized in
myelin synthesis (Chakraborty and Ledeen, 2003; Tansey and
Cammer, 1988), not surprisingly, a signiﬁcant proportion of cyto-
solic ACC is detectable in puriﬁed myelin (Chakraborty and Ledeen,
2003) and the activity of ACC in oligodendrocytes in rats is highest
during the neonatal myelinating period (DeWille and Horrocks,
1992; Tansey et al., 1988). The relative contribution of ACC1 and
ACC2 to ACC activity in the brain is not known. However, in human
adult brain (RNA pooled from multiple donors), ACC1 RNA was
found to be approximately twice as abundant as ACC2 RNA (Castle
et al., 2009). Furthermore, levels of murine ACC are signiﬁcantly
reduced in the sciatic nerve of the trembler mouse model of pe-
ripheral nervous system dysmyelination compared with normal
mice (Salles et al., 2003). Finally, malonyl-CoA, the product of the
reaction catalyzed by ACC, is used as the two-carbon building block
for fatty acid synthesis by the brain microsomal fatty acid elon-
gating system for deposition in myelin (DeWille and Horrocks,
1992). Malonyl-CoA also coordinates the balance between fatty
acid synthesis and fatty acid oxidation. As cytosolic levels of
malonyl-CoA increase, the rate of fatty acid synthesis increases; as
peri-mitochondrial levels of malonyl-CoA from the reactioncatalyzed by ACC2 increase, carnitine palmitoyltransferase 1 (CPT1)
is inhibited and the rate of fatty acid transport into mitochondria
decreases leading to reduced fatty acid beta oxidation (Foster, 2012;
McGarry et al., 1978). Therefore, high-dose biotinmay be acting as a
promyelinogenic agent through its role as a cofactor for ACC1 and
ACC2.
The normalization of visual evoked potential latency observed
in one MS patient with chronic visual loss after 9 months' treat-
ment with MD1003 is consistent with myelin repair (Sedel et al.,
2015). A progressive decrease in the choline/creatine ratio was
observed with magnetic resonance spectroscopy in a second pa-
tient with prominent optic nerve involvement; the ratio normal-
ized completely after 9 months of treatment with MD1003.
Elevations of choline, the core component of the hydrophilic head
of membrane phospholipids, are commonly observed in MS pla-
ques and are thought to result from the breakdown of the phos-
pholipid membrane that occurs during inﬂammation, gliosis, and
demyelination (Arnold et al., 1992; Narayana, 2005). We speculate
that normalization of the choline/creatine ratio overtime after
treatment with MD1003 reﬂects progressive myelin repair
accompanied by a decrease in free choline release from mem-
branes. In addition, the delay in onset of clinical beneﬁt (2e8
months) seen in MS patients treated with MD1003 is consistent
with remodeling of the myelin sheath. Remodeling of the myelin
sheath is believed to occur at a relatively slow rate. MRI studies in
patients with acute gadolinium (Gd)-enhancing lesions suggest
that the process of remyelination takes an average of 7 months
(Chen et al., 2008).
Remyelination of denuded axons is a logical and attractive
strategy for the treatment of progressive MS (Franklin and Ffrench-
Constant, 2008; Zawadzka and Franklin, 2007). Extensive regen-
erative remyelination occurs in some patients with early MS but is
typically reduced as the disease progresses (Goldschmidt et al.,
2009; Miron et al., 2011; Prineas et al., 1993). Remyelination has
been documented in both active and inactive MS lesions (Miron
et al., 2011), and remyelination strategies stimulate functional re-
covery in animal models of MS (Bai et al., 2012; Deshmukh et al.,
2013; Duncan et al., 2009). The process underlying remyelination
is complex and is thought to involve the maturation and migration
F. Sedel et al. / Neuropharmacology 110 (2016) 644e653648of OPCs and numerous promoting and inhibitory factors (Munzel
and Williams, 2013). However, by increasing the supply of the
two carbon units required for fatty acid elongation (the funda-
mental building block of myelin), high-dose biotin acting through
ACC is an attractive candidate for a novel promyelinogenic agent.5.2. High-dose biotin in the reversal of virtual hypoxia
Aswell as promoting remyelination through its role as a cofactor
for ACC, high-dose biotin may also be targeting cellular energy
levels. Several lines of evidence suggest that cellular energy
deprivation secondary to demyelination is responsible for the
progressive irreversible neuronal degeneration observed in pro-
gressive MS (Luessi et al., 2012; Stys et al., 2012). In the normal,
myelinated neuron, the nerve impulse is conducted along the
length of the axon in discreet jumps spreading along the chain of
nodes of Ranvier, which contain high densities of voltage-gated Naþ
and Kþ channels (Fig. 2) (Rasband and Trimmer, 2001). This pro-
cess, termed saltatory conduction, not only increases the speed at
which the nerve impulse is propagated compared with nerve im-
pulses in unmyelinated axons, but also reduces neuronal energy
expenditure because ATP is only needed to restore the restingFig. 2. Increased axonal energy demand as a result from axon demyelination. Nerve
impulses in myelinated axons propagate between the nodes of Ranvier. Depolarization
of the membrane is triggered by the transient opening of voltage-gated Naþ ion
channels. Repolarization is achieved through voltage-gated Kþ ion channels, which
restore electrical conditions, followed by restoration of the ionic distribution by the
ATP-dependent Naþ/Kþ ATPase pump. ATP consumption is greatly increased in
demyelinated axons due to redistribution of ion channels along the length of the
denuded axon.membrane potential at the nodes of Ranvier. Restoration of the
resting membrane potential is mainly achieved by the ATP-
dependent Naþ/Kþ pump (Naþ/Kþ ATPase) (Krishnan et al., 2009).
Loss of the insulating myelin sheath causes the loss of saltatory
conduction and thereby increases the energy required for nerve
propagation. In denuded axons, voltage-gated Naþ channels are
redistributed along the length of the axon (Fig. 2). This compen-
satory mechanism reﬂects a switch from saltatory to continuous
conduction (Craner et al., 2004; Levin et al., 2014). This switch is
accompanied by an increase in the number of mitochondria in the
demyelinated axons as a result of the neuron's attempt to supply
the increased energy demand required to maintain the intracel-
lular/extracellular ion gradients (Witte et al., 2009). However, evi-
dence suggests that, in MS patients, axonal ATP production is
simultaneously compromised due to defects in their neuronal
mitochondria (Dutta et al., 2006; Mahad et al., 2009; Su et al.,
2009). The resulting imbalance between energy supply and en-
ergy demand causes a state of ‘virtual hypoxia’ which may be the
trigger for neuron degeneration (Luessi et al., 2012; Trapp and Stys,
2009). If insufﬁcient ATP is available for Naþ/Kþ ATPase to restore
the membrane potential, the neuron will enter a state of depolar-
ization characterized by a further inﬂux of Naþ. This state can
activate the Naþ/Ca2þ exchanger in reverse mode, leading to an
increase in intra-axonal Ca2þ as Naþ ions are removed from the
neuron (Trapp and Stys, 2009). Excessive levels of Ca2þ in the
neuron can activate a number of Ca2þ-mediated degenerative
pathways (Trapp and Stys, 2009). In chronic MS lesions, axonal
levels of Naþ/Kþ ATPase are decreased, which may exacerbate the
state of membrane depolarization (Young et al., 2008).
We hypothesize that treatment with high-dose biotin reverses
this state of virtual hypoxia through its role as a cofactor for PC,
MCC, and PCC. These three enzymes are central to aerobic energy
production and generate intermediates for the tricarboxylic acid
(TCA) cycle (Fig. 3) (Tong, 2013). All three of these enzymes are
known to be expressed in astrocytes and neurons (Ballhausen et al.,
2009; Hassel, 2000). PC catalyzes the conversion of pyruvate toFig. 3. Biotin increases ATP production in axonal mitochondria. Biotin is a co-enzyme
for PC, PCC, and MCC, three carboxylases involved in the metabolism of pyruvate and
amino acids. These three enzymes are expressed in neurons and their actions ulti-
mately result in the production of key intermediates of the TCA cycle including
oxaloacetate, acetyl-CoA and succinyl-CoA. The TCA cycle produces one ATP molecule
for every acetyl-CoA used. We hypothesize that high doses of biotin may result in
increased ATP production in demyelinating neurons.
F. Sedel et al. / Neuropharmacology 110 (2016) 644e653 649oxaloacetate, thus serving an essential anaplerotic role by replen-
ishing the 4-carbon “backbone” of the TCA cycle. PCC generates
methylmalonyl-CoA from propionyl-CoA, which is then converted
to succinyl-CoA by methylmalonyl-CoA mutase. MCC plays a role in
the metabolism of leucine and ultimately leads to production of
acetyl-CoA. Thus, these three biotin-dependent carboxylases feed
the TCA cycle at three different entry points (oxaloacetate, succi-
nate, and acetyl-CoA) and could be expected to increase the levels
of cellular ATP at the rate of one molecule of acetyl-CoA used by the
TCA cycle producing one molecule of ATP. Indeed, nutritional biotin
deﬁciency and biotin deﬁciency induced by knocking out the
recycling enzyme biotinidase cause severe ATP depletion
(Hernandez-Vazquez et al., 2012, 2013; Velazquez-Arellano et al.,
2011). By increasing the available intraneuronal pool of ATP, high-
dose biotin may reduce demyelinated neural dysfunction and the
adverse effects of hypoxia (Lazzarino et al., 2010; Trapp and Stys,
2009).
In progressive MS, the proportion of mutant mitochondria in-
creases through clonal expansion of mitochondrial DNA deletions
(Campbell et al., 2011). As a consequence, some neurons still
possess functional mitochondria, while others have damaged
mitochondria or a mixture of functional and damaged mitochon-
dria (heteroplasmy; Mahad et al. (2015)). In this latter case, the
remaining pool of mitochondria with functional respiratory chain
enzymes may not be sufﬁcient to compensate for the increase in
energy demand occurring in chronically demyelinated axons. It
could be anticipated that only axons with some remaining healthy
mitochondria would beneﬁt from the treatment with high-dose
biotin.
A similar hypothesis has been the basis for testing idebenone in
progressive MS (Spindler et al., 2009) (NCT00950248 and
NCT01854359). Increasing cellular energy production is also
thought to be the mechanism by which idebenone (Catena®, San-
thera Pharmaceuticals), a synthetic analog of coenzyme Q10 exerts
its therapeutic activity. This compound is a substrate for reduction
by two NAD(P)H:quinone oxidoreductases (NQO1 and NQO2)
(Haefeli et al., 2011). The reduced form of idebenone is believed to
pass electrons into the mitochondrial respiratory chain triggering
an increase in cellular ATP levels. Of note, experiments in the
chronic experimental autoimmune encephalomyelitis (EAE) mouse
model failed to demonstrate any effect of idebenone in preventing
or attenuating disability (Fiebiger et al., 2013).
Several other mechanisms by which biotin may be exerting a
therapeutic effect exist. Biotin is a key transcriptional regulator of
several genes involved in glucose and lipid metabolism. In vitro and
in vivo studies have shown that elevated biotin levels can upregu-
late the expression of hepatic and pancreatic glucokinase, insulin,
and the insulin receptor, and downregulate hepatic phosphoenol-
pyruvate carboxykinase (Chauhan and Dakshinamurti, 1991;
Dokusova and Krivoruchenko, 1972; Leon-Del-Rio, 2005; Marshall
et al., 1980; Pacheco-Alvarez et al., 2002; Romero-Navarro et al.,
1999). Interestingly, biotin also regulates the expression of two of
the carboxylases for which it acts as a cofactor (PC and ACC1), and
of HCLS (Pacheco-Alvarez et al., 2004). The mechanism by which
biotin regulates gene expression remains elusive. Biotin was
initially thought not to be a natural modiﬁer of histones (Healy
et al., 2009), However, biotinylation sites are known to be present
on histones H2A, H3, and H4 (Zempleni et al., 2012b) and several
studies have demonstrated that biotinylation of histones by HCLS
induces chromatin remodeling that can regulate gene expression
(Filenko et al., 2011; Gralla et al., 2008; Kuroishi et al., 2011;
Wijeratne et al., 2010). However, more recent data suggests that
HCLS itself may interact directly with chromatin as part of a multi-
protein gene regulating complex (Liu and Zempleni, 2014;
Zempleni et al., 2012a). Currently, an effect of biotin on MSthrough control of gene expression by modiﬁcation of chromatin
structure remains speculative.6. Feasibility of high-dose biotin as a therapy for progressive
MS
Several characteristics of high-dose biotin make it an attractive
therapeutic option in progressive MS. Biotin demonstrates high
(~100%) bioavailability (Zempleni and Mock, 1999) and is able to
cross the blood brain barrier (Spector and Mock, 1988b). The ability
to dose orally will greatly facilitate treatment for individuals with
MS and consequently a high level of treatment compliance can be
expected. While the body of preclinical toxicology data for high-
dose biotin is limited, the available data indicates that only mar-
ginal adverse effects are observed in animals treated with biotin
doses in the hundreds of milligrams per kilogram of body weight
range (Hathcock, 2015). Adverse events in patients with progres-
sive MS treated with MD1003 (100e300 mg/day) were infrequent;
occurring in three of 23 (13%) patients treated in the compassionate
use open-label trial (Sedel et al., 2015). Two patients experienced
transient diarrhea and one patient died from cardiac failure 36
months after treatment onset. This patient exhibited mild aortic
valvulopathy with dilatation of the ascending aorta together with a
ﬁrst-degree atrio-ventricular block which were found 18 months
after treatment onset; no relation could be established between
treatment onset, mild cardiac abnormalities and death. Whether
these abnormalities existed before treatment is unknown.
A signiﬁcant teratogenic effect on rabbit fetuses during the
period of organogenesis was observed in pregnant rabbits treated
with high-dose biotin (30 mg/kg/day; approximately twice the
equivalent human dose currently under investigation based on the
surface area conversion table; unpublished data, MedDay Phar-
maceuticals). These effects included a higher incidence of malro-
tated paw (11.8%), domed head (4.1%), hydrocephaly (4.1%) and
liquid content in the cranial cavity (4.7%) compared with control
rabbits and those treated with 15 mg/kg/day biotin. Consequently,
high-dose biotin may not be suitable for administration to women
with MS who are pregnant or considering pregnancy. Fingolimod,
teriﬂunomide and interferon beta-1a are also contraindicated in
pregnant women (although pregnancy may start while the patient
is receiving interferon beta-1a) (Biogen Idec Ltd, 2014; Novartis
Europharm Ltd, 2011; Sanoﬁ-Aventis Group, 2013). Control of
pregnancy is recommended prior to each infusion of natalizumab
and discontinuation of treatment should be considered if a women
becomes pregnant while taking this drug (Biogen Idec Ltd., 2011).
Overall, high-dose biotin appears to be a practical and well-
tolerated therapeutic option in patients with progressive MS,
particularly when compared with currently approved treatments
for MS that have some signiﬁcant safety and tolerability concerns.
Patients receiving ﬁngolimod require close monitoring due to the
risk of serious cardiovascular complications, infections, and mac-
ular edema (Wingerchuk and Carter, 2014). Monoclonal antibodies
such as natalizumab and alemtuzumab require parenteral admin-
istration which can be inconvenient for patients, and these agents
have potentially serious side effects, such as the risk of developing
progressive multifocal leukoencephalopathy with natalizumab
(Bloomgren et al., 2012) and idiopathic thrombocytopenic purpura
and antibody-mediated immune diseases for alemtuzumab (Cuker
et al., 2011). While nonmyeloablative hematopoietic stem cell
transplantation appears to be a promising treatment option for
patients with RRMS (Burt et al., 2015), this procedure will not be
suitable for all patients and is associated with signiﬁcant risks.
Fig. 4. Overview of putative mechanism of action of high-dose biotin in multiple
sclerosis. Targets of biotin are: (a) ACC: acetyl-CoA carboxylase (b) PC: pyruvate
carboxylase, (c) PCC: propionyl-CoA carboxylase, (d) MCC: methylcrotonyl-CoA
carboxylase. Activation of ACC may increase myelin synthesis in oligodendrocytes
and remyelination whereas activation of PC, PCC, and MCC may lead to increase ATP
production in neurons (and astrocytes).
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directions
In summary, we hypothesize that high-dose biotin treatment
is targeting two key pathophysiological mechanisms in progres-
sive MS: (1) by triggering myelin synthesis by oligodendrocytes
and (2) by replenishing ATP in hypoxic neurons (Fig. 4). Targeting
both demyelination and neurodegeneration is likely to be
important in the treatment of progressive MS. Although several
other therapeutics that target one of these processes are currently
under investigation in patients with MS, high-dose biotin might
be simultaneously preventing the hypoxia-driven neuro-
degeneration of neurons and promoting the remyelination of
axons.Table 1
Ongoing phase IIB/III randomized, double-blind, placebo-controlled trials of MD1003 (30
Study
name
Primary objective Primary efﬁcacy endpoint
MS-SPI To demonstrate the superiority of
MD1003 at 300 mg/day over placebo in
clinical improvement of patients with
spinal progressive MS
Proportion of patients with decre
EDSSa or 20% improvement in T
month 9 (conﬁrmed at month 12
compared with best baseline valu
MS-ON To demonstrate the superiority of
MD1003 at 300 mg/day over placebo in
the visual improvement of patients
suffering from chronic visual loss after
optic neuritis related to MS
Mean change in best corrected vi
acuity (logMAR) at 100% contrast
baseline and month 6 of the dise
MD1003-
AMN
To demonstrate the superiority of
MD1003 at 300 mg/day over placebo in
the clinical improvement of patients
with AMN
Mean change of 2MWT time betw
month 12 and baseline
2MWT, 2 min walking test; AMN, adrenomyeloneuropathy; EDSS, Expanded Disability St
Timed 25-Foot Walk.
a Deﬁned as a decrease of 0.5 point if initial EDSS from 6 to 7 and a decrease of 1
b Deﬁned as the eye with the worst visual acuity (<5/10) at baseline and with evidenThe efﬁcacy and safety of MD1003 is currently under investi-
gation in three multicenter phase III placebo-controlled trials in
patients with progressive MS involving either the spinal cord or
chronic visual loss after optic neuritis, and in patients with AMN
(Table 1). The study in patients with spinal progressive MS repre-
sents a particularly ambitious evaluation of high-dose biotin as a
therapy for MS, because the patients recruited to this trial have
relatively severe disease: PPMS or SPMS fulﬁlling revisedMcDonald
criteria (Polman et al., 2011) and Lublin criteria (Lublin and
Reingold, 1996) with clinical evidence of spastic paraparesis and
signiﬁcant disability (EDSS scores 4.5e7). Furthermore, this is the
ﬁrst trial of an investigational MS therapy that has chosen a
reduction in MS-related disability as the primary efﬁcacy endpoint
of the trial, as measured by one of two validated clinical assessment
scales (the EDSS and the TW25). Results from all three trials are
expected in 2015e2016. Several in vivo studies that will further
investigate the pharmacodynamic effects of high-dose biotin are
also currently underway.
The potential mechanism of action of high-dose biotin in pro-
gressive MS is still partly speculative and there is a striking lack of
pre-clinical data on the exactmechanism of action. Some important
gaps in knowledge remain to be elucidated experimentally:
(1) Are biotin or malonyl-CoA limiting factors for remyelination
in chronic MS lesions? This might be addressed using in vitro
models such as OPCs.
(2) Does biotin have an impact on myelination or remyelination
in vivo? This could be assessed in relevant animal models
with and without inﬂammation such as experimental auto-
immune encephalomyelitis, cuprizone or toxin-induced
demyelination.
(3) Does high-dose biotin increase ATP production by mito-
chondria in chronic MS lesions? This might be assessed in
relevant in vitro and in vivo models.Author contributions
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